Gara Jalqabaatti › Kansa Endometiriyaalii › Massachusetts › Boston
Qorannoo klinikaalii Kansa Endometiriyaalii Boston, MA keessatti
Qorannoo 50 Kansa Endometiriyaalii f Boston fi naannoo isaa (kilomeetira 30 keessatti) hirmaatuu jiru. Qorannoo banaa eenyu akka hirmaatu fi akkamitti garee qorannoo akka quunnaman ilaali.
Takkalaa qorannoo (Ingiliffa)
Qorannoo hirmaatuu barbaadduu? Fuula kana jalatti agarsiisi — $99 guyyaa 30f →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Namoota walitti qabaa jiraSadarkaa 2
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
Namoota walitti qabaa jira
- Dana-Farber Cancer Institute, Boston
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Dana-Farber Cancer Institute, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Namoota walitti qabaa jiraSadarkaa 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Dana Farber Cancer Institute, Boston
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Research Site, Boston
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
- Dana Farber / Harvard Cancer Center, Boston
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute Brookline Avenue, Boston
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Namoota walitti qabaa jiraSadarkaa 2
- Massachusetts General Hospital Cancer Center, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Dana Farber Cancer Institute, Boston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Namoota walitti qabaa jiraSadarkaa 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Namoota walitti qabaa jiraSadarkaa 3
- Tufts Medical Center ( Site 6052), Boston
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
ALPINE: Maintenance Letrozole/Abemaciclib
Namoota walitti qabaa jiraSadarkaa 2
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Dana Farber Cancer Institute, Boston
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
Namoota walitti qabaa jiraSadarkaa 1
- Dana-Farber Cancer Institute, Boston
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Dana-Farber Cancer Institute, Boston
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Namoota walitti qabaa jiraSadarkaa 3
- Research Site, Boston
Concurrent Laparoscopic Hysterectomy and Weight Loss Surgery in Obese Patients With Endometrial Carcinoma or Endometrial Intraepithelial Neoplasia
Namoota walitti qabaa jira
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Mass General Cancer Center, Boston
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Dana-Farber Cancer Institute, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Dana-Farber Cancer Institute, Boston
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Dana Farber Cancer Institute, Boston
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Research Site, Boston
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Namoota walitti qabaa jiraSadarkaa 2
- Dana Farber Cancer Institute, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of PHST001 in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1
- Dana Farber Cancer Institute, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital Cancer Center, Boston
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
Namoota walitti qabaa jiraSadarkaa 1
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4175408 in Participants With Advanced Cancer
Namoota walitti qabaa jiraSadarkaa 1
- Massachusetts General Hospital, Boston
RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Massachusetts General Hospital Cancer Center, Boston
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- Dana-Farber Cancer Institute, Boston
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Namoota walitti qabaa jiraSadarkaa 1
- Mass General Brigham Cancer Institute, Boston
- Dana Farber Cancer Institute, Boston
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
Namoota walitti qabaa jira
- Dana Farber Cancer Institute, Boston
Avelumab and M1774 in ARID1A-mutated Endometrial Cancer
Namoota walitti qabaa jiraSadarkaa 2
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Namoota walitti qabaa jiraSadarkaa 2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Namoota walitti qabaa jiraSadarkaa 1/2
- Dana Farber Cancer Institute, Boston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Namoota walitti qabaa jiraSadarkaa 1/2
- Massachusetts General Hospital, Boston
Comprehensive Outcomes for After Cancer Health
Namoota walitti qabaa jiraHojjettoota fayyaa simatamoo
- Dana Farber Cancer Institute, Boston
Qorannoo Kansa Endometiriyaalii magaalota biroo keessatti
- Houston, TXQorannoo 68
- New York City, NYQorannoo 52
- Arlington, VAQorannoo 39
- Nashville, TNQorannoo 38
- Los Angeles, CAQorannoo 34
- St. Louis, MOQorannoo 29
- Philadelphia, PAQorannoo 28
- San Antonio, TXQorannoo 27
- Chicago, ILQorannoo 25
- Columbus, OHQorannoo 25
- Queens, NYQorannoo 25
- Oklahoma City, OKQorannoo 25
Qorannoo biroo Boston keessatti
- Saree OljooQorannoo 111
- Kansara Qara'a Non-Small CellQorannoo 90
- Saree (Gosoota Hunda)Qorannoo 86
- Kansarii ColorectalQorannoo 63
- Kansara MetastatikiiQorannoo 63
- Dhibee QaraQorannoo 62
- Kansarii OvariiQorannoo 61
- Kansarii ProstateQorannoo 59
- DepreshiniiQorannoo 52
- Cufama OnneeQorannoo 44
- Leukemia Myeloidii HamaaQorannoo 44
- Kansarii PancreasQorannoo 43
Kanneen ClinicalTrials.gov irraa argaman, daataa 05-Onk-2026 irratti argame. Qorannoon hundi isaa kan ofii qajeelfama qoodfannaa qaba; gareen qorannoo eenyu akka hirmaatu murteessa.